Lynx Therapeutics Overview
- Founded
-
1992
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
3
Lynx Therapeutics General Information
Description
Developer of genetic analysis technologies for pharmaceutical, biotechnology and agricultural industries. The company's cloning and sequencing technologies provide comprehensive and quantitative digital gene expression data which is important to systems biology research enabling drug discovery and development companies to research, develop and implement new treatments for improving human health.
Contact Information
Website
www.lynxgen.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Primary Office
- 25861 Industrial Boulevard
- Hayward, CA 94545
- United States
Lynx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lynx Therapeutics Patents
Lynx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2003243720-A1 | Method for detecting foreign dna in a host genome | Inactive | 21-Jun-2002 | 00000000000 | |
| US-20040086912-A1 | Using fluorescent activated cell sorting to identify cells comprising heterologous nucleotide sequences; disease resistant plants; tissue engineering | Inactive | 21-Jun-2002 | 00000000000 | 0 |
| US-20030206832-A1 | Includes a patterned seal having a specified arrangement of holes and groves, and an connection plate having passages corresponding to the holes in the seal. | Inactive | 02-May-2002 | 000000000000 | |
| US-20030170700-A1 | Modulating phenotypes; genetic engineering; adjust cholesterol concentration in blood | Inactive | 09-Jan-2002 | 000000000 | 00 |
| US-20030180764-A1 | A set of polynucleotide sequences that are differentially regulated in response to cholesterol and adipogenesis | Inactive | 09-Jan-2002 | G01N33/92 |
Lynx Therapeutics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kevin Corcoran | Board Member, President & Chief Executive Officer |
Lynx Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lynx Therapeutics Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 07-Mar-2005 | 0000000 00 | Biotechnology | ||
| 000000 000000 | 11-Dec-2001 | 000000000 | 000.00 | Drug Discovery | |
| Axaron Bioscience | 23-Oct-1996 | Joint Venture | Drug Discovery |
Lynx Therapeutics Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 0000000000 | 11-Dec-2001 | 000000000 | 000.00 | Completed |
|
| Axaron Bioscience | 23-Oct-1996 | Joint Venture | Completed |
|